Induction Therapy With a Single High Dose Bolus of Intravenous Methotr
An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results.
What it found
The trial ended early for another reason (see below).
Reason given: Lack of funding
What was tested
Treatment tested
- Interferon beta-1a
Interferon alpha/beta receptor agonist
- Methotrexate
Dihydrofolate reductase inhibitor
- Methylprednisolone
Glucocorticoid receptor agonist
Who could take part
MS (type not specified) · 18 to 50
Show the full criteria
Inclusion criteria
To be eligible for entry into this study, candidates must meet the following eligibility criteria at the time of enrollment, which are the same as in the CHAMPS study [1]: * Between the ages of 18 and 50 years, inclusive. * As in the CHAMPS study [1] patients must have had a first isolated, well-defined neurologic event consistent with demyelination and involving the optic nerve (unilateral optic neuritis), spinal cord (incomplete transverse myelitis), or brain stem or cerebellum (brain stem or cerebella syndrome). They must also have two or more clinically silent lesions of the brain that were at least 3 mm in diameter on MRI scans and were characteristic of MS (at least one lesion must be periventricular or ovoid). * The onset of the visual or neurological symptoms must have occurred no more than twelve days before the MTX treatment, so that the methylprednisolone treatment is begun no more than fourteen days after the onset of symptoms, as in CHAMPS. * Patients must give written informed consent prior to any testing under this protocol, including screening tests and evaluations that are not considered part of the subject's routine care.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and a one-time high dose intravenous methotrexate with Leucovorin rescue, along with the standard solumedrol treatment before beginning AVONEX® treatment.
Papers
Loading reviews and guidelines…
Related trials
- An Observational Study to Learn About the Interferon-beta Exposure of
Running, not recruiting
Still running
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
Phase 2 · Stopped early
Stopped
- US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage a
Completed
No results found
- Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocogn
Status unknown
Paper found, not read
- PROmyBETAappGame: a Study to Learn More About the Medication Usage & P
Completed
No results found
- Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CL
Recruiting
Still running
History
Started
May 2002
Main results due
Dec 2002
Finished
Dec 2002